On behalf of the Board of Directors of the New York Society of Addiction Medicine (NYSAM), I want to welcome you to NYSAM’s 13th Annual “Intersection of Science, Treatment, and Policy” Conference. As in prior years, the agenda on the first conference day highlights important policy issues affecting our patients, particularly with respect to access to care. On the second day, the focus is clinical, with important updates on neuroscience; the application of rTMS to addiction, depression, and pain management; the use of toxicology testing for both alcohol and opioids; the care of hospitalized opioid-dependent patients; and recent developments in designer opioids and the tools toxicologists use to monitor the rapid changes in this area.

This year, for the first time in its history, NYSAM invited residents throughout NY State to submit brief presentations addressing how addictions impact the applicant’s specialty practice, patients, and/or training program. We received many excellent presentations and have invited two residents to present their submissions on Friday afternoon. In addition, we have also asked an addiction medicine fellow to present on his experiences applying the principles of SBIRT in the emergency department.

Finally, we have asked Dr. Herbert Kleber, one of the giants in our field, to give our keynote address on Saturday immediately before lunch. As someone blessed to have heard Dr. Kleber speak on many occasions, I can assure you that the keynote will be informative, stimulating, and engaging.

We hope that you find the conference extremely valuable, and we also hope that the conference powerfully stimulates your interest in NYSAM. If so, we invite you to show that interest either by joining NYSAM or becoming more involved in our Committees and/or Board. Also, on Friday evening, please be sure to attend our Annual Membership meeting as well as the Gala Dinner, which will feature a most interesting discussion of lessons learned about weaponized fentanyl analogues from the Moscow theater re-capture in 2003.

Thank you for participating in this conference.

Sincerely,

Eric Collins, MD
NYSAM President
A BIG THANK YOU TO OUR 2017 NYSAM CONFERENCE SPONSORS

Acacia Network
Adapt Pharma
Alkermes
Behavioral Health of the Palm Beaches
Braeburn Pharmaceuticals
Cottonwood Tucson
Footprints to Recovery
Hazelden Betty Ford Foundation
Kaiser Permanente/The Permanente Medical Group, Inc.
Kaléo, Inc.
Laboratory Corporation of America
Lakeview Health
Lifeskills South Florida
Mallinckrodt Pharmaceuticals
Maryland Recovery
McLean Hospital
MedicaSafe
The National Center on Addiction and Substance Abuse
Northeast & Carribean Addiction Technology Transfer Center
Orexo US, Inc.
Professional Risk Management Services, Inc. (PRMS)
Silver Hill Hospital
Sovereign Health Group
START Treatment and Recovery Centers
Truetox Laboratories, LLC
Westbridge
West-Ward Pharmaceutical Corp.
Friday, February 3, 2017—Public Policy Forum

10:00 am—12:00 pm  Public Policy Committee Meeting (NYSAM Members only—Room 401/402)

1:00 pm—2:45 pm  New Initiatives to Expand Access to Medication Assisted Treatment of Opioid Addiction in NY State

Hillary Kunins, MD – NYC DOH-MH

This presentation will review the epidemiology of overdose in NYC, describe current and new initiatives in NYC with a focus on expanded access to medication-assisted treatment.

**Hillary Kunins** is the Assistant Commissioner for the Bureau of Alcohol and Drug Use at the Department of Health and Mental Hygiene (DOHMH) and a general internist with certification in addiction medicine. Since 2012, when Dr. Kunins joined the Department as Assistant Commissioner, she has led the Department’s efforts to promote public health approaches to reducing the health and social consequences of drug and alcohol use in NYC, including reducing prescription opioid misuse and excessive alcohol use; promoting best practices in integrating substance use care in primary systems; prevention of overdose; and surveillance and reporting on drug and alcohol use. Before joining the Department, she worked in the Bronx for 16 years providing primary and addiction-related care to patients in both community health centers and in substance abuse treatment programs.

Narelle Ellendon, RN - NYS DOH Office of Drug User Health

Decades of research has shown that medication-assisted treatment (MAT) with buprenorphine (known as “Suboxone” or “Subutex”) or methadone help people overcome their opioid dependence, reduce HIV and hepatitis transmission and at the same time protect people from experiencing an opioid overdose. Buprenorphine is the first medication approved to treat opioid dependence in a primary care setting, yet despite this strong evidence and opportunities for utilization, buprenorphine points of access are not meeting the needs of our communities. NYSDOH will present on the challenges and activities to increase buprenorphine access across the state.

**Narelle Ellendon**, is a Registered Nurse and the Opioid Program Manager as part of the New York State Department of Health's, Office of Drug User Health. Narelle is the lead in coordinating the expansion of Buprenorphine access across the state. Prior to working for the health department, Narelle was the Director of Capacity Building Services for Harm Reduction Coalition overseeing their national training and capacity building services to support the integration and expansion of drug user health interventions, including syringe access services, overdose prevention services, Hepatitis C and HIV prevention, screening, care and treatment.
The opioid crisis has resulted in enormous heartache, loss and devastation to individuals, families and society in New York State. OASAS, along with others from state agencies, has traveled throughout the state and listened to New Yorkers in order to develop responses that will serve the needs that are identified by the people who are actually affected. Today’s presentation will focus on some of the results of these efforts. Examples of items that will be covered in the presentation include: a real time treatment availability tool; tools that exist online to start discussions with patients and in community forums that practitioners can use themselves or make available to their patients and communities; discussion of enhanced services such as family navigators, peer engagement specialists, and new treatment sites; development of an opioid educational series for prescribers and information to be distributed by pharmacists to patients when they pick up prescriptions for controlled substances; as well as new insurance laws for treatment access and addiction medication; adolescent clubhouses and recovery centers; and new opportunities for OTPs to expand services.

Charles W. Morgan, MD, DFASAM, FAAFP, DABAM serves as Medical Director of the New York State Office of Alcoholism and Substance Abuse Services. Dr. Morgan is a Distinguished Fellow of the American Society of Addiction Medicine and a Fellow of the American Academy of Family Physicians, and has worked in the field of Addiction Medicine for over three decades. He did his graduate work in Human Genetics at Cornell University, and his residency work in Internal Medicine in Rochester, NY, and Anesthesiology at the University of Pennsylvania. He has taught residents, fellows, physicians, nurse practitioners, physicians’ assistants, counselors and other professionals throughout his career from across the country and other parts of the world, and has been recognized by the American Academy of Family Physicians for his teaching. Dr. Morgan’s expertise includes all levels of care including outpatient treatment, inpatient rehabilitation and detoxification, and extended care, as well all modalities of treatment including Medication Supported Recovery as well as Recovery without using medications.

ASAM’s Payer Relations Committee has been working with a number of payers to improve payment policies for addiction treatment over the past eighteen months. The efforts have concentrated on improving prior authorization policies and improving access to appropriate, quality addiction treatment. Additionally, as the health care system moves away from fee-for-service payments and toward models that focus on quality of care, ASAM is working to develop an alternative payment model that should improve addiction treatment by paying for supportive care that is rarely paid for in our current payment system.

Jackie Le Grand joined the American Society of Addiction Medicine in July 2015 as the Manager, Payer Relations, where she advocates for improved payment policies for addiction treatment. Previously, she worked on state health policy issues, including ACA implementation and Medicaid, for the National Academy for State Health Policy and on public health issues, including opioid use, for the National Governors’ Association. She has a BA in Communication from Boston College and a Master of Public Policy in Health Policy from Brandeis University.
3:40 pm—4:10 pm  Possible Impact of the New Federal Administration on the Provision and Payment for Addiction Treatment - Corey Waller, MD

Given the recent changes in the Federal Government there are many things that are likely to flux when it comes to payment for and the treatment of addiction. Some of these include the possible block granting of Medicaid, the restructuring of the SAMHSA block grant and the regulations that are being written after the passage of the Comprehensive Addiction and Recovery Act (CARA) and the 21st Century CURES act. There are also pending regulations on 42 CFR pt 2 and the expansion of Buprenorphine prescribing by Nurse Practitioners and Physician Assistants. In this session we will give the 30,000 ft view of these issues and the likely impacts to follow.

Corey Waller MD, MS, FACEP, DFASAM is an addiction, pain, and emergency medicine specialist and now the Senior Medical Director for Education and Policy at the National Center for Complex Health and Social Needs/Camden Coalition of Healthcare Providers (CCHP). In this role he is responsible for developing and maintaining all on-line training and live technical assistance delivered by the National Center. This covers addiction, pain, behavioral health, system development, payment model implementation and healthcare policy. Before joining the National Center/CCHP he worked for the Spectrum Health System in Grand Rapids, Michigan, which is a fully integrated health system with 11 hospitals and over 1000 employed physicians. He was the Medical Director of the Spectrum Health Medical Group Center for Integrative Medicine, the Medical Staff Chief of Pain Medicine to the Spectrum Health Hospital System, the President of the Michigan Society of Addiction Medicine, as well as SUD Medical Director at Lakeshore Regional Partners (Community Mental Health-Region 3). Dr. Waller earned a Master’s of Science in Biology with a neuromolecular focus at Southwest Texas State University and earned his Medical Degree at the University of Texas Medical School in San Antonio.

4:10 pm—5:00 pm  Presentations from medical residents and fellows from across the state on how addiction affects their specialty - Aaron Fields, MD, Andrea Jakubowski, MD and team, and Jocelyn Young, MD

Teachable Moments: Applying the principles of SBIRT to addiction-related problems in the Emergency Department—Aaron Fields, MD

NYSAM Resident Competition Winners

Prescribing take-home naloxone at an urban medical center: A resident-led pilot project—Andrea Jakubowski, MD, Primary Care and Social Internal Medicine, PGY2, Montefiore Medical Center/Albert Einstein College of Medicine, Alexi Pappas, Lee Isaacsohn, Felipe Castillo, Masyukova, Richard Silvera, Evan Rausch, Louisa Holaday, Sameen Farooq and Ashley Ceniceros.

Effects of Education on Resident Attitude Toward Opioids and Addiction—Jocelyn Young, DO, University of Rochester Family Medicine Residency, PGY 2
Carfentanil Past and Present: The 2002 Moscow theatre hostage crisis and its 2016 reemergence as a lethal agent in the current opioid epidemic—Paul Wax, MD (45 minutes)

Initially developed as a sedating agent for large animals, carfentanil is an extraordinary powerful fentanyl analog about 10,000 times as potent as morphine. While never definitively confirmed at the time, carfentanil was used by the Russian authorities in 2002 as a knock-down agent in an attempt to retake a Moscow theatre from Chechen rebels where more than 850 theatre goers had been held hostage. Unfortunately about 130 of the hostages died from the toxic affects of carfentanil. In 2016 reports first surfaced that this same chemical, carfentanil, was identified in an increasingly large number of inadvertent opioid fatalities as the opioid epidemic continues to grow. This talk will review the Moscow Theatre seige and discuss the pharmacological properties of this most potent of all the opioids.

Paul Wax, M.D., FACMT, Executive Director of the American College of Medical Toxicology. Dr. Wax received his B.A. from Dartmouth College, his M.D. from the Mount Sinai School of Medicine, his Emergency Medicine training at the UCLA Hospitals, and his Medical Toxicology training at Bellevue Medicine Center / New York University. He is Board-certified in both Medical Toxicology and Emergency Medicine, and is a Fellow of the American College of Medical Toxicology. Along with his part time role as the Executive Director of ACMT, Dr. Wax is a Clinical Professor in Surgery (Emergency Medicine) at the University of Texas, Southwestern School of Medicine where he is a member of the Section of Medical Toxicology and Director of the Medical Toxicology Clinic. Before joining ACMT in 2008 as its Executive Director, and the University of Texas Southwestern in 2006 as a part-time faculty member, Dr. Wax had faculty appointments in the Departments of Emergency Medicine at the University of Rochester School of Medicine from 1991-2001 and the University of Arizona School of Medicine from 2001-2006.
Leading the future of health care.

**ADDITION MEDICINE PHYSICIANS**
Northern & Central California

We are currently interviewing for Addiction Psychiatrists and Addiction Specialists. Fellowship in Addiction Psychiatry strongly preferred but not required for psychiatrists. Addiction Fellowship is required for internal medicine and family medicine physicians.

**PLEASE STOP BY OUR BOOTH AT THE NYSAM CONFERENCE**
For more information on our opportunities, please stop by our booth at the NYSAM Conference.

For Northern California Opportunities:
Please contact Nicholas Chastain at (510) 625-4759 or Nicholas.Chastain@kp.org.

For Central Valley Opportunities: (Modesto, Stockton & Fresno)
Please contact Ken Baker at (510) 625-6331 or Kenneth.Baker@kp.org.

KAISER PERMANENTE®
The Permanente Medical Group, Inc.

http://physiciancareers-ncal.kp.org
We are an EOE/AA/WM/F/D/V Employer. YEVRAA Federal Contractor

---

McLean Signature Recovery Programs

**Overcoming addiction requires understanding addiction.**

The clinical expertise at McLean Hospital's Signature Recovery Programs is guided by the latest evidence-based treatment and recovery methods, helping treatment resistant adults reclaim their lives at two exceptional locations.

STOP BY THE McLEAN HOSPITAL BOOTH FOR MORE INFORMATION.

McLean Fernside
Princeton, MA

McLean Borden Cottage
Camden, ME

LEARN MORE AT SignatureRecovery.org OR 844.599.3008
CONFERENCE PROGRAM
NYSAM 13th ANNUAL INTERSECTION OF SCIENCE, TREATMENT AND POLICY CONFERENCE

Saturday, February 4, 2017

7:00 am—7:45 am  Mutual Help Meeting (Room 403)

7:00 am—9:00 am  Registration and Continental Breakfast

7:45 am—8:45 am  Clinical Cases Presentation and Discussion - Edwin Salsitz, MD and R. Jeffrey Goldsmith, MD

Interesting clinical cases will be presented. Audience participation is encouraged, for suggestions on diagnoses and appropriate management.

**Dr. Edwin A. Salsitz** has been an attending physician in the Beth Israel Medical Center, Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Medicine at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings, and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine. Dr. Salsitz is the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee.

**Dr. Goldsmith** is President of the American Society of Addiction Medicine (2015-2017). He is a Professor of Clinical Psychiatry in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati. He teaches fellows in three programs: Psychiatry, Medicine and Addiction Medicine and lectures first and second year students about addiction in the University’s College of Medicine. Dr. Goldsmith joined the University of Cincinnati VA Medical Center full time starting in 1994 where he has held a variety of roles involving patient care and research. Dr. Goldsmith directed the Dual Diagnosis Services, provided psychiatric consultations for the hospital and led research with the NIDA Clinical Trials Network. Dr. Goldsmith also created an integrated Primary Care Mental Health program with the Director of Primary Care which continues to be active. Currently, Dr. Goldsmith works in the VA Buprenorphine Treatment Clinic. Dr. Goldsmith received his medical training at the University of Cincinnati College of Medicine and finished his residency in Psychiatry at the University of Cincinnati. He is board certified in psychiatry and addiction medicine. He is a Distinguished Fellow of the American Society of Addiction Medicine and a Distinguished Lifetime Fellow of the American Psychiatric Association.

8:45 am—9:00 am  Welcome – Eric Collins, MD, Edwin Salsitz, MD – NYSAM

9:00 am—10:30 am  Neuroscience Symposium - Yasmin Hurd, PhD, Erin Calipari, PhD, Gabor Egervari, MD, and Muhammad Parvaz, PhD

This symposium will present recent neuroscience research findings in a variety of addictive disorders pre-clinical and clinical research findings will be presented and discussed.

**Dr. Yasmin Hurd** is the Ward Coleman Chair of Translational Neuroscience and Professor of Psychiatry and Neuroscience at the Icahn School of Medicine in New York, USA. She is an internationally renowned neuroscientist whose translational research examines the neurobiology of drug abuse and related psychiatric disorders. She is highly published in the field and leads a team of investigators in molecular biology, behavioral neuropharmacology, genetics and neuroimaging to study the human brain as well as translational animal models. Dr. Hurd is also Director for the Center for Addictive Disorders within the Mount Sinai Behavioral Health System which covers one of the largest addiction populations in the US providing clinical care supported by science-based medicine and advanced state-of-the-art research. She served as the Director of the MD/PhD program for four years at Mount Sinai in line with her career that has focused on mentoring students.
9:00 am—10:30 am  Erin S. Calipari's research seeks to characterize and modulate the precise circuits in the brain that underlie both adaptive and maladaptive processes in reward, motivation, and associative learning, to develop improved treatments for drug addiction. As a graduate student at Wake Forest School of Medicine, Dr. Calipari worked in the laboratory of Dr. Sara Jones studying the neurochemical alterations driving addictive behaviors. The major goal of these studies was to determine the consequences of self-administered cocaine, methylphenidate and amphetamine on dopamine system signaling in an effort to determine factors that may predict drug abuse vulnerability and provide novel molecular targets for pharmacotherapeutics. Her current work aims to combine novel and innovative techniques to extend our understanding of the circuit and molecular mechanisms of reward learning and motivation and their role in addiction.

Gabor Egervari, MD—After graduating from the Semmelweis University School of Medicine in Budapest, Hungary in 2011, Dr. Gabor Egervari joined Dr. Yasmin Hurd's laboratory at Icahn School of Medicine at Mount Sinai as a NIDA INVEST Drug Abuse Research Fellow. In 2012, Dr. Egervari enrolled in Mount Sinai's Neuroscience Graduate Program. Currently, a PhD candidate in Dr. Hurd's lab, studying the molecular underpinnings of heroin use disorder that could guide the development of future targeted therapeutic interventions.

Muhammad A. Parvaz is an Assistant Professor in the Departments of Psychiatry and Neuroscience at Icahn School of Medicine at Mount Sinai. He received his PhD in Biomedical Engineering from Stony Brook University (Advisor: Dr. Rita Goldstein) and subsequently completed a NIDA-funded Postdoctoral Fellowship at Brookhaven National Lab and at ISMMS. Dr. Parvaz's research focuses on using multimodal neuroimaging techniques (EEG and MRI) to study reward sensitivity (both drug and non-drug-related) and emotion dysregulation in drug addiction. Currently, his research involves studying craving induced by drug-related cues in individuals with substance use disorders seeking treatment and developing and testing an EEG-assisted cognitive intervention to alleviate negative affect in cocaine addiction based on real time neurofeedback training.

10:30 am—10:50 am  Coffee Break (Exhibitor Hall)

10:50 am—11:40 am  Transcranial Magnetic Stimulation for Addiction, Depression, and Pain Management
Ricardo Cruciani, MD

Recent research demonstrates the effectiveness of transmagnetic therapy in the treatment of pain, addiction and depression. The evidence supporting the effectiveness of Transcranial Magnetic Stimulation will be reviewed.

Ricardo A. Cruciani, MD, PhD is Chairman of the Department of Neurology and Professor of Neurology, Adjunct Professor of Physiology and Pharmacology at Drexel University College of Medicine, and is the Director of the Center for Pain Palliative Medicine at the same Institution. Prior to this position he was Chief of Neurology and Director of the Pain Center at Capital Health, NJ. Before he was Vice-Chairman, Director of the Pain Division and Director of the Center for non-Invasive Brain Stimulation of New York in the Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, NY, NY. He was also Professor of Clinical Neurology and Clinical Anesthesiology at Albert Einstein College of Medicine also in New York City. He has a PhD in pharmacology (Summa Cum Laude equivalent) and was a Visiting Fellow and later an Associate Researcher at the National Institutes of Health (NIH) where he trained in opioid pharmacology and neurophysiology. Then he trained in Neurology at Albert Einstein College of Medicine and Neurology and Psychiatry at Weill College of Medicine at Cornell University, and in Pain Management at Memorial Sloan Kettering Cancer Center all in New York. His main research interests are opioid pharmacology, neuropathic pain and brain stimulation for the management of chronic pain syndromes.
CONFERENCE PROGRAM
NYSAM 13th ANNUAL INTERSECTION OF SCIENCE, TREATMENT AND POLICY CONFERENCE

Saturday, February 4, 2017

11:40 am—12:30 pm  Keynote Address: "My Career in Addiction - Where is the Field Going and Are We Making Progress?" - Herbert Kleber, MD

Herbert D. Kleber, MD, Professor of Psychiatry and Director Emeritus of the Division of Substance Abuse, Columbia University. Dr. Herbert Kleber is Professor of Psychiatry and Founder and Emeritus Director of the Division on Substance Abuse at the Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute since 1992. Before that, Dr. Kleber served for 2 1/2 years as the Deputy Director for Demand Reduction at the Office of National Drug Control Policy under President George H. W. Bush and Director William Bennett. Prior to the government position, he was Professor of Psychiatry at Yale University School of Medicine (1966-89) where he founded and directed the Substance Abuse Treatment Center. The Columbia/NYSPI Division has become one of the leading substance abuse centers in the country, with research on new medications to treat individuals with cocaine, heroin, prescription opioids, marijuana, alcohol, and nicotine problems and the psychosocial approaches that accompany them. His undergraduate education was Dartmouth College, his medical training at Thomas Jefferson Medical School, and his psychiatric residency at Yale University School of Medicine. Following his residency, he spent two years at the U.S. Public Health Service Hospital in Lexington, Kentucky. He then returned to Yale where he began the Drug Dependence Unit in 1968. Dr. Kleber is the author or co-author of more than 250 papers, chapters, and books dealing with all aspects of substance abuse, the co-Editor of the American Psychiatric Press Textbook of Substance Abuse Treatment now in its 5th Edition, and the Chair of the APA Substance Abuse Practice Guidelines Committee. He has received numerous awards, two honorary degrees, is listed as one of the “Best Doctors in America” and “Best Doctors in New York” is on the editorial board of five scientific journals, and was elected in 1996 to be a member of The Institute of Medicine of the National Academy of Science.

12:30 pm—2:00 pm  Lunch Sponsored by Sovereign Health

Using Measurement-Based Care to Enhance Substance Use Disorders and Mental Health Treatment - Dr. Tonmoy Sharma, CEO, Sovereign Health Group (45 minutes)

Research studies have demonstrated that there is enormous variation in the quality of substance abuse and mental health care in the US. There are significant gaps between clinical practice and evidence-based treatment (EBT) as well as wide variation in other clinical processes of care. Measurement-based care (MBC) can be defined as the practice of basing patient care on data collected throughout treatment. MBC is considered a core component of numerous evidence-based practices. MBC has trans-theoretical and trans-diagnostic relevance with broad reach across clinical settings. MBC provides insight into treatment progress, highlights ongoing treatment targets, reduces symptom deterioration, and improves patient outcomes. There are many different models of MBC but each share common features of measurement, diagnosis and intervention. The empirical support for MBC use will be reviewed along with guidance for successful implementation of MBC.

Tonmoy Sharma, CEO of Sovereign Health, has been recognized with numerous awards, honors and grants for his work in advancing mental health and its treatment in the United States, Europe and Southeast Asia. He is a prolific researcher and scientist, and the author or co-author of more than 200 peer-reviewed articles and five books on schizophrenia and mental illness. Sharma has served on numerous editorial boards, acted as peer reviewer for 14 international medical journals, and has been on various advisory boards governing the development of antipsychotics. As a member of the Royal College of Psychiatrist's London, Changing Minds Campaign, he helped lead a five-year initiative to combat the stigma of CNS illness. He currently co-hosts KABC 790 AM's In Your Right Mind, a cutting-edge, weekly radio show that covers various topics on the latest headlines in behavioral health.
A NATIONAL BEHAVIORAL HEALTHCARE SYSTEM

Sovereign Health provides innovative, gender-specific behavioral health treatment to adolescents, adults and their families. Our individualized care begins with intensive diagnostic assessments and includes treatment for cognitive deficits and a recovery management program following discharge.

TREATMENT SERVICES
- Mental Health
- Addiction/Dual Diagnosis
- Trauma
- Pain Management
- Eating Disorders

866.327.0865
www.sovhealth.com
24/7 Helpline | Most Insurances Accepted

National Treatment Locations
San Clemente, CA | Los Angeles, CA | San Diego, CA | Palm Desert, CA | Chandler, AZ | Delta, UT | El Paso, TX | Fort Myers, FL | Pompano Beach, FL
## CONFERENCE SCHEDULE AT-A-GLANCE

NYSAM 13th ANNUAL INTERSECTION OF SCIENCE, TREATMENT AND POLICY CONFERENCE

### Friday, February 3, 2017 — Public Policy Forum

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 am – 12:00 pm</td>
<td>Public Policy Committee Meeting (NYSAM Members only - Room 401/402)</td>
</tr>
<tr>
<td>1:00 pm - 2:45 pm</td>
<td>New Initiatives to Expand Access to Medication Assisted Treatment of Opioid Addiction in NYS</td>
</tr>
<tr>
<td>2:45 pm – 3:00 pm</td>
<td>Coffee Break (Exhibitor Hall)</td>
</tr>
<tr>
<td>3:00 pm – 3:40 pm</td>
<td>Overcoming Obstacles to MAT-Increasing Participation Through Payment Reform and Insurance Incentives</td>
</tr>
<tr>
<td>3:40 pm – 4:10 pm</td>
<td>Possible Impact of the New Federal Administration on the Provision and Payment for Addiction Treatment</td>
</tr>
<tr>
<td>4:10 pm – 5:00 pm</td>
<td>Presentations from medical residents and fellows from across the state on how addiction affects their specialty</td>
</tr>
<tr>
<td>5:15 pm – 6:00 pm</td>
<td>NYSAM Annual Membership Meeting (NYSAM Members Only—Room 401/402)</td>
</tr>
<tr>
<td>6:00 pm – 8:00 pm</td>
<td><strong>Gala Dinner Event</strong></td>
</tr>
</tbody>
</table>

### Saturday, February 4, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am—7:45 am</td>
<td>Mutual Help Meeting (Room 403)</td>
</tr>
<tr>
<td>7:00 am – 9:00 am</td>
<td>Registration and Continental Breakfast</td>
</tr>
<tr>
<td>7:45 am - 8:45 am</td>
<td>Clinical Cases Presentation and Discussion</td>
</tr>
<tr>
<td>8:45 am - 9:00 am</td>
<td>Welcome</td>
</tr>
<tr>
<td>9:00 am - 10:30 am</td>
<td>Neuroscience Symposium</td>
</tr>
<tr>
<td>10:30 am - 10:50 am</td>
<td>Coffee Break (Exhibitor Hall)</td>
</tr>
<tr>
<td>10:50 am - 11:40 am</td>
<td>Transcranial Magnetic Stimulation for Addiction, Depression, and Pain Management</td>
</tr>
<tr>
<td>11:40 am - 12:30 pm</td>
<td><strong>Keynote Address:</strong> “My Career in Addiction. Where is the Field Going and Are We Making Progress?”</td>
</tr>
<tr>
<td>12:30 pm – 2:00 pm</td>
<td>Lunch Sponsored by Sovereign Health</td>
</tr>
<tr>
<td></td>
<td>Using Measurement-Based Care to Enhance Substance Use Disorders and Mental Health Treatment (45 minutes)</td>
</tr>
<tr>
<td></td>
<td>Resources for Treating Addiction in Adolescents - (30 minutes)</td>
</tr>
<tr>
<td>2:00 pm - 2:50 pm</td>
<td>The 80 Hour Alcohol Test</td>
</tr>
<tr>
<td>2:50 pm - 3:40 pm</td>
<td>Hospital Care of the &quot;Narcotic Addict&quot;</td>
</tr>
<tr>
<td>3:40 pm – 4:00 pm</td>
<td>Coffee Break (Exhibitor Hall)</td>
</tr>
<tr>
<td>4:00 pm – 4:50 pm</td>
<td>Developments in the Illicit Opioid Market: Tools for monitoring the changing landscape of synthetic designer opioids</td>
</tr>
<tr>
<td>4:50 pm – 5:40 pm</td>
<td>Medical Toxicology Panel – Synthetic Opioids and the Opioid Overdose Epidemic</td>
</tr>
</tbody>
</table>
12:30 pm—2:00 pm

Resources for Treating Addiction in Adolescents - Kevin Kunz, MD (30 minutes)

All physicians, especially primary care physicians, have multiple opportunities to advocate prevention or offer therapeutic interventions to adolescents, other youth and their caregivers. Yet, the advice physicians receive on this topic has been widely divergent and does not guide simple, effective and straightforward messaging to the adolescent population. To address this deficiency, the National Center of Physician Training in Addiction Medicine convened a work group of expert physicians in the fields of addiction medicine and adolescent medicine. The guidance of this expert group resulting from its comprehensive review will be presented. A compendium on the subject will be made available (with no-cost CME attached). Specifically recommended screening and assessment tools, practical physician-specific training materials for delivering SBIRT, and other materials and policies on this topic, including guidance on treatment and referrals will be presented. Other information will include reimbursement and billing codes, materials to provide teen patients, resources for families, friends and educators, and other physician course offerings.

Kevin Kunz is Executive Vice President of the American Board of Addiction Medicine (ABAM) and The Addiction Medicine Foundation (TAMF). He is an ABAM Diplomate, on the faculty of the University of Hawaii School of Medicine and is a diplomate of the American Board of Preventive Medicine. Dr. Kunz has received local, state and national recognition for his contributions to addiction prevention and treatment. He is a recipient of several awards, including the Clinician of the Year Award from the Hawaii Medical Association and the Annual ASAM Award. He served as the first President of ABAM and TAMF from 2008-2011. Dr. Kunz is a Section Editor of the Principles of Addiction Medicine and co-authored the introductory chapter of Essentials of Addiction Medicine: A Public Health Approach to Prevention – The Health Professional’s Role. He previously served as a Director at the American Society of Addiction Medicine and co-chair of the ASAM Medical Specialty Action Group, which recommended in 2006 that an independent medical board be established to improve the care of patients and to formally involve the medical community and all of health care in the prevention and treatment of unhealthy substance use and addiction.

2:00 pm—2:50 pm

The 80 Hour Alcohol Test & More: Novel Biomarkers of Alcohol Exposure
Michael Holland, MD, FACMT

This presentation will discuss biomarkers of alcohol exposure from breath testing and blood alcohol analysis, which test for current intoxication, to urinary longer-term alcohol use markers which can only document prior use or exposure and not impairment/intoxication. We will discuss limits of each type of test, the useful window of assessment, and pros and cons of each test, and their proper application in a given clinical, medico-legal, or regulatory environment. Most specifically, actual cases and results and how to interpret them in the face of alcohol abstinence monitoring by the addiction specialist will be presented.

Michael G. Holland, MD, FACTX, FACOEM, FACMT, FACEP—Dr. Holland is an Associate Professor of Emergency Medicine at SUNY Upstate Medical University, Co-Director of the Medical Toxicology Fellowship Training Program and Medical Toxicologist at the Upstate New York Poison Center at SUNY Upstate, all in Syracuse, NY. He is also Director of Occupational Medicine at Glens Falls Hospital Center for Occupational Health in Glens Falls, NY, and Senior Medical Toxicologist at the Center for Toxicology and Environmental Health in Little Rock, AR. Dr. Holland completed his second three-year term on the ACOEM Board of Directors in 2015, as well as six years as co-chairman of the ACOEM Council of Scientific Advisors. He served on the Board of Directors of the Medical Review Officers Certification Council (MROCC) for 12 years, and has supervised the drug and alcohol testing program at Glens Falls Hospital for over twenty years. In this capacity, he reviews drug and alcohol tests for employers as well as court-mandated and professional monitoring programs. Dr. Holland lectures extensively on occupational and environmental toxicology subjects, indoor air quality, pulmonary toxicology, and drug and alcohol impairment at the state, national and international levels, as well as on the subject of post-mortem toxicology and cause-of-death analysis.
Your patients in recovery are making great strides towards a brighter future and West-Ward is committed to supporting you as you encourage them to live free from dependence. We take great pride in aiding the unique needs of the Addiction Therapy community.

Addiction Therapy Services
888.831.2183.
west-ward.com
2:50 pm—3:40 pm  Hospital Care of the "Narcotic Addict” – JoAn Laes, MD

Dr. Laes will describe options used to treat opioid withdrawal in the Emergency Department and hospital setting; the 3-day emergency rule related to non-x waiver emergency use for the treatment of opioid dependence related to use of Buprenorphine or methadone; the process of ED and hospital induction using Buprenorphine or methadone and linkage to an outpatient or inpatient treatment program through case-based examples; the treatment of pain in the emergency setting for patients maintained on Buprenorphine or Naltrexone; and how methadone maintenance affects clinical care related to opioid dependence for patients in methadone maintenance programs seen in the ED or hospital setting.

JoAn Laes, MD is an addiction medicine physician at Hennepin County Medical Center in Minneapolis, Minnesota, focusing on inpatient addiction medicine and toxicology consultation as well as outpatient treatment of opioid and other substance use disorders. She is also a consulting medical toxicologist for the Minnesota Poison Center, Minneapolis, Minnesota, Medical Director for Missions Inc. detox facility in Plymouth, Minnesota and a nocturnist at Mercy Hospital in Coon Rapids, Minnesota. She is board certified in Internal Medicine, Medical Toxicology, and Addiction Medicine. She completed internal medicine residency at Hennepin County Medical Center and medical toxicology fellowship at Regions Hospital in St. Paul, Minnesota.

3:40 pm—4:00 pm  Coffee Break (Exhibitor Hall)

4:00 pm—4:50 pm  Developments in the Illicit Opioid Market: Tools for Monitoring the Changing landscape of Synthetic Designer Opioids - Barry Logan, PhD

Analytical laboratories that support both clinical and forensic clients are struggling to keep up with a diverse range of novel opioid and other designer drugs in the US drug supply. Laboratories, usually, only find what they are looking for; meaning that novel compounds can be a blind spot for many labs. This presentation will compare typical approaches to drug screening in the emergency room and in forensic laboratories, and review some of the challenges presented by the recent innovations in drugs of abuse including synthetic opioids, fentanyl analogs, and derivatives. This includes risks of false positives and false negatives in routine drug screening procedures. In addition, the presentation will review some of the findings regarding trends in opioid derivatives and case studies of fatal intoxications associated with acetylfentanyl, butyrylfentanyl, furanylfentanyl, U-47700, and others.

Dr. Barry K. Logan is Sr. Vice President of Forensic Science Initiatives Chief Scientist at NMS Labs in Willow Grove, Pennsylvania, where his responsibilities include management of toxicology resources, new test design and development, and expert testimony in forensic toxicology and chemistry. Dr. Logan is a Fellow of the American Board of Forensic Toxicologists (ABFT), and has over one hundred (100) publications and four hundred (400) presentations in forensic toxicology and analytical chemistry, including work on the effects of methamphetamine, cocaine and marijuana on drivers, drug caused and related death. His recent work has focused on the analytical and interpretive toxicology of emerging recreational and designer drugs. Dr. Logan’s other appointments include Executive Director of the Robert F. Borkenstein course at Indiana University, and Executive Director at the Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieders Family Renaissance Foundation in suburban Philadelphia. He holds academic appointments at Indiana University, Arcadia University and Thomas Jefferson University.
4:50 pm—5:40 pm  Medical Toxicology Panel – Synthetic Opioids and the Opioid Overdose Epidemic  
Tim Wiegand, MD, FACMT - Moderator

Michael Holland, MD, FACMT, JoAn Laes, MD, Barry Logan, PhD, Ross Sullivan, MD

Treatment of heroin and other opioid overdoses can be a challenging clinical dilemma, in particular as synthetic and designer opioids have become increasingly prevalent. Fentanyl analogues and other ultra-potent opioids have been substituted for and added into heroin or pressed into tablets with other drugs and sold as counterfeit prescription medications. The toxicology panel features experts in toxicology and forensic medicine discussing management and clearance after overdose from these drugs, challenges unique to detoxification and withdrawal for patients dependent on these opioids, toxicologic identification of these compounds and other challenges unique to the synthetic opioid problem overall. This session will include interactive discussion with the audience participating.

Timothy J. Wiegand, MD, FACMT, FAACT is Director of Toxicology at the University of Rochester in Rochester, New York. He holds faculty appointments as an Associate Clinical Professor of Emergency Medicine at Strong Memorial Hospital and Highland Hospital in Rochester, New York and is adjunct faculty and consultant toxicologist for the SUNY Upstate Poison Center and SUNY Upstate Medical Toxicology Fellowship. In addition to these faculty positions Dr. Wiegand serves as Medical Director for the Monroe County chemical dependence treatment program Huther Doyle and is a consultant detoxification and acute opioid and alcohol withdrawal management specialist for the Syracuse Behavioral Health (SBH) Rochester, New York detoxification facility site. Dr. Wiegand completed a combined fellowship at the University of California San Francisco in Medical Toxicology & Clinical Pharmacology. He has worked with several Poison Centers throughout his tenure as Medical Toxicologist including as Director for the Ruth Lawrence Poison & Drug Information Center in Rochester, New York, before state budget cuts forced the centers closure. Some of his areas of interest include cost-effective analysis of toxicology practice, billing and reimbursement for toxicology consultation, and treatment of drug and alcohol dependence. Dr. Wiegand won the American Society of Addiction Medicine (ASAM) 2013 (Chicago, IL) Medical Scientific Committee Award for the best abstract submission on Addictions Training during Medical Toxicology Fellowship and has been a speaker on Pharmacology & Toxicology content for the annual ASAM Review Course. In 2014, Dr. Wiegand joined the NYSAM Board as Communication Committee Chair.

Disclosure of Off-Label/Investigational Uses of Products:

- Yasmin Hurd—presentation will include discussion possibly of Cannabidiol.
- Herbert Kleber—presentation will include discussion of investigational use of Ketamine for treating cocaine and Psilocybin for treating patients with significant cancer-related anxiety and depression.
- JoAn Laes—presentation will include discussion of sublingual tablets for pain.
Acacia Network, the leading Latino integrated care nonprofit in the nation, offers members of the community, from children to seniors, a pathway to behavioral and primary healthcare, housing, and empowerment. As visionary leaders in transforming the triple aim to triple integrated care, Acacia champions a collaborative environment to deliver vital health, housing and community building services. Acacia’s behavioral health services care for people with substance and/or mental illness within a comprehensive set of 31 programs including detoxification; adult, youth, and women and children residential treatment; ambulatory treatment including medication assisted treatment; mental health outpatient and strength based day treatment, community residences, and supportive housing. Primary health care is delivered through 7 health care centers, 5 of which are FQHCs, along with our Medicaid certified Health Home, outpatient programs, and skilled nursing facility for people with HIV. Academic enrichment and supports are delivered in over 15 academic enhancement programs, and our 7 senior centers provide meals and social and cultural activities. People in need of housing find stability, case management, and community affiliation in our transitional, supportive, and affordable housing units. All of our tenants are part of the larger Acacia Network family and linked to our fully integrated services.

Adapt Pharma is an innovative small business focused on developing cutting-edge treatments for patients with special medical conditions. Our mission is to provide simple, reliable, and accessible therapeutic options, ensuring that patients, and those who care for them, have access to the right treatment at the right time.

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.

Behavioral Health of the Palm Beaches is a leading South Florida behavioral healthcare organization which is comprised of four highly specialized Palm Beach County facilities. They offer a complete menu of addiction and mental health treatment services, including medical detox, state-of-the-art rehab, and discharge and aftercare planning.

Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in neuroscience. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges. Braeburn’s commercial product, Probuphine® (buprenorphine) implant was approved by the FDA in May 2016. Braeburn’s investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Braeburn’s pipeline products are at various stages of clinical development and include weekly and monthly CAM2038 subcutaneous injection depot formulations of buprenorphine, being investigated in opioid addiction and pain, BB0417 buprenorphine/granisetron injectable for acute pain, and BB0817, six-month risperidone implant being investigated in schizophrenia.

Cottonwood Tucson is a co-occurring disorders treatment facility for adults. Cottonwood Tucson offers a unique treatment approach to recovery, putting health and wellness as the central component of healing from addiction and behavioral health disorders. For more information about Cottonwood Tucson and the programs they offer, visit www.cottonwooddetucson.com or call toll free 1-800-877-4520.
Footprints to Recovery is comprised of premier drug, alcohol and substance use disorder rehabilitation centers. We pride ourselves on having designed intimate centers which promote highly individualized treatment for our patients throughout our continuum of care. Our team of experts is comprised of full-time nursing staff and dually licensed therapists. Our team utilizes proven evidence-based therapies to assist in helping our patients to build a personal plan of wellness and recovery.

The Hazelden Betty Ford Foundation is a force of healing and hope for individuals, families and communities affected by addiction to alcohol and other drugs. It is the nation’s largest nonprofit treatment provider, with a legacy that began in 1949 and includes the 1982 founding of the Betty Ford Center. With 16 sites in California, Minnesota, Oregon, Illinois, New York, Florida, Massachusetts, Colorado and Texas, the Foundation offers prevention and recovery solutions nationwide and across the entire continuum of care for youth and adults. Visit us at: Hazeldenbettyford.org.

Within The Permanente Medical Group, Inc., physicians find recognition, stability, opportunity, and independence. Through our leadership in the use of advance technology, our creation of innovative solutions and our influence on health policy and reform efforts, Kaiser Permanente is helping to shape the future of health care in the nation. Beyond the practice of medicine, our physicians are provided with many personal and professional opportunities, including research, teaching, and participation in leadership activities. In addition, our physicians donate countless hours of their time by volunteering to help the causes of hundreds of community health organizations.

We offer competitive salaries and a generous benefits package. Incentives may be available to you to compensate for experience, training, and geographic choice. We invite you to contact us today to discover how you can become a part of our new, innovative model or practice. https://physiciancareers-ncal.kaiserpermanente.org/

LabCorp makes available drug screening profiles designed to assist treatment professionals with monitoring patients’ drug use. In addition to detecting commonly abused prescription and illicit drugs, LabCorp’s Substance Abuse Recovery options test for medications commonly used to treat addiction, such as Suboxone® (buprenorphine) and methadone. We also offer ethyl glucuronide (EtG) and ethyl sulfate (EtS) to extend the detection time of alcohol use, and offer tests for contemporary abuse of substances such as synthetic cannabinoids.

Lakeview Health located in Jacksonville, FL serves individuals with addiction and psychiatric disorders. Licensed clinical staff work in large and small groups to offer an integrative health approach that addresses the medical, psychological, physical and spiritual aspects of recovery. Our gender-responsive programs, the Rose of Lakeview and the Star of Lakeview host unique treatment features that cater to men and women independently. We provide a full continuum of care that includes medical detox to intensive outpatient, allowing patients to successfully move toward a life in recovery. Call us at 866-460-8416 or visit us at www.lakeviewhealth.com.
Since 1991, Lifeskills offers residential, transitional and outpatient psychiatric and substance abuse treatment for adults ages 18+ who may also be facing challenges with trauma, OCD, personality disorders, bipolar, major depression, anxiety and schizophrenia. Located in Deerfield Beach, Florida, Lifeskills provides caring, clinical treatment in a safe environment for adults focused on long-term recovery.

Although lengths of stay typically average 3-4 months, we achieve positive outcomes because we do not put recovery on a timetable. The length of stay is entirely dependent on the unique needs of our clients, complexity of their condition and rate at which progress is made. Clients are challenged to move as quickly as they are able toward community reintegration and achieving their personal treatment goals. Clients at Lifeskills can expect to participate in the implementation of a treatment plan in partnership with doctorate and master level clinicians, targeted on long term recovery and community reintegration.

Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Mallinckrodt provides key products for customers with a broad portfolio of specialty generics to treat pain, ADHD, opiate and alcohol addiction, depression and insomnia. Visit www.mallinckrodt.com to learn more.

Maryland Recovery is a Joint Commission accredited, extended care program for substance abuse and mental health. We offer Partial Hospitalization and Intensive Outpatient Levels of Care. We are a 12-week program that helps individuals learn to begin to live again after facing their substance abuse and mental health concerns. Clients participate in a clinical programming with a holistic approach to treatment and are under the care of our Medical and Psychiatric team. We offer the treatment and the time needed to help individuals and families heal and live again.

The alcohol and drug treatment services at Harvard Medical School-affiliated McLean Hospital offers comprehensive care. We specialize in treatment plans that address the primary addiction as well as accompanying co-occurring psychiatric disorders. As part of our Signature Recovery Programs, McLean Borden Cottage and McLean Fernside provide unparalleled treatment in unsurpassed settings. For more information or for admissions, please contact:

Phone: 800.906.9531
Email signaturerecovery@partners.org
MedicaSafe has been awarded multiple grants by the National Institutes of Health (NIH) to develop innovative medication technology. Research partners include the VA Hospital in Seattle, Stanford Medical School and Mt. Sinai Hospital. Our mission is to help clinicians treat patients with opioid addiction safely, effectively, and with equity. Through our Smart Dispenser, online portal, and telehealth platform, we deliver a convenient and integrated treatment system that enables clinicians to remotely track medication usage, detect misuse, and deter diversion.

The National Center on Addiction and Substance Abuse is a national nonprofit research and policy organization focused on improving the understanding, prevention and treatment of substance use and addiction. Since 1992, our interdisciplinary experts have collaborated with others to create and share the tools and resources needed to combat substance use and addiction. We conduct and synthesize research, inform and guide the public, evaluate and improve healthcare, and analyze and recommend effective policies and practices.

NDRI-USA, Inc. is a not-for-profit social and behavioral health training organization with a 25 year history of public health service in the New York Metropolitan region, nationally, and internationally. NDRI-USA’s mission is to reduce health disparities by creating sustainable change facilitated by innovative approaches to training and technical assistance. By promoting the advancement of state-of-the-art techniques, evidence-based, and promising practices, we help practitioners to bridge the gap between research and practice. Areas of concentration include but are not limited to substance use, mental illness, HIV/HCV/STI prevention and treatment, cultural competency, health care reform, and criminal justice populations, with training and technical assistance focused on the adoption and implementation of related evidence-based practices. Training and technical assistance is provided via webinars, self-paced online courses, hub-and-spoke network technology, face-to-face workshops, and hands-on individualized consultation. Services include needs assessment, curriculum development, and evaluation.

Orexo US, Inc., a specialty pharmaceutical company with a mission to advance the treatment of opioid dependence and support patient care. We recognize opioid dependence is a long standing problem and have made a commitment to advancing evidence based treatment.

PRMS® manages The Psychiatrists’ Program®, a full-service medical professional liability insurance program for behavioral healthcare providers unparalleled in its risk management expertise, aggressive defense strategies, and specialized policy. Administrative defense coverage up to $50,000.* Telepsychiatry and forensic services included at no additional cost. Premium discounts up to 60%.

*May vary by state.
Founded in 1931, Silver Hill Hospital is a nationally recognized nonprofit psychiatric hospital located 50 miles north of New York City. Silver Hill provides evidence-based inpatient and residential treatment for adults with psychiatric and/or addictive disorders, including chronic pain. Silver Hill is distinct in offering a full continuum of care: acute inpatient services, residential Transitional Living, Intensive Outpatient Programs, and an Outpatient Addiction Program. silverhillhospital.org

Sovereign Health is a nationally recognized behavioral health care company accredited by The Joint Commission. We offer treatment for all behavioral health issues, including addiction, mental health conditions, dual diagnosis and eating disorders. We also provide medically supervised detox (both medication and nutritionally assisted). What separates Sovereign Health from other treatment providers is our tailored treatment plans. Each patient undergoes a thorough assessment during intake. This assessment serves two purposes. First, it addresses all physical and mental health issues the patient may have. (Nearly 9 million Americans each year experience co-occurring substance abuse and mental health disorders.) Second, our clinicians use the information gathered during the assessment to construct the individualized treatment regimen. This regimen evolves as the patient progresses through treatment.

Sovereign Health uses the latest evidence-based therapies to ensure every patient receives the highest quality behavioral health treatment. We offer treatment programs specific to patient demographics. For example:

- Our Chandler, Arizona, facility is female-only. Our Chandler staff specializes in treating domestic violence survivors.
- Our Rancho San Diego location is an adolescent treatment facility. We emphasize programs specific to this demographic, including treating anorexia, bulimia and other eating disorders.
- Our Palm Desert facility provides Personal Recovery Integrating Men’s Experiences (P.R.I.M.E.) program for men over 40. This innovative treatment focuses on the issues peculiar to this age group.

Sovereign combines traditional therapies – individual and group counseling, peer-to-peer groups, cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT) – with experiential and innovative therapies, such as music, art and equine therapy, yoga and other therapies that focus on movement and mindfulness.

At Sovereign, our treatment philosophy is simple: Each patient is unique and is deserving of unique treatment.

Sovereign accepts most private insurances, making treatment affordable. Visit our website at www.sovcal.com to watch patient reviews as they share their experiences of hope and recovery.”
For admission related queries, dial (866) 327-0865 today.
To provide the highest quality of compassionate, comprehensive, evidence-based healthcare and social services; education of the public concerning maintenance of healthy lifestyles; and cutting-edge behavioral, biomedical and healthcare services research. START is dedicated to transforming the perception of addiction and behavioral health disorders by bringing dignity and respect to the lives, families and communities we serve.

START Treatment & Recovery Centers is a nonprofit organization certified by the New York State Office of Alcoholism and Substance Abuse Services (OASAS); licensed as an Article 28 Diagnostic and Treatment Center by the New York State Office of Health Systems Management; and is one of the nation’s top 3%, evidenced-based healthcare providers accredited by the Commission on Accreditation of Rehabilitation Facilities (CARF).

TRUETOX™ Laboratories provides the highest quality of service to clinicians and clients by providing continuous education and latest laboratory techniques keeping offices updated on various medication monitoring programs. TRUETOX™ Laboratories will always provide the clinicians and clients with competent and reliable clinical laboratory results. We hold ourselves to the highest standards of compliance and ethics possible.

WestBridge is a private, non-profit organization dedicated to providing evidence-based treatment to individuals and their families that experience co-occurring mental illness and substance use disorders. We provide a fully integrated continuum of community-based services, including residential treatment, and family education and support to help individuals and their families achieve a healthy life of recovery.

Headquartered in Columbus, OH, West-Ward Pharmaceuticals is a recognized leader for the research, development, sales, and marketing of multisource pharmaceutical products. Specific to Addiction Treatment, West-Ward Pharmaceuticals offers Methadone HCI Oral Concentrate, Diskets® Dispersible Tablets as well as Buprenorphine HCI Sublingual Tablets and Buprenorphine HCl and Naloxone Sublingual Tablets. Please contact Addiction Therapy Customer Support at 888-831-2183 if you would like to learn more about our products and services.

This live activity, NYSAM’s 13th Annual Statewide "Intersection of Science, Treatment and Policy" Conference, with a beginning date of 02/03/2017, has been reviewed and is acceptable for up to 12.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMA/AAP Equivalency:
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AAMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

Social Work CEUs:
Alcoholism and Substance Abuse Providers of New York State, Inc. (ASAP) is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0396. ASAP is a collaborator with NYSAM and has approved NYSAM’s 13th Annual Statewide "Intersection of Science, Treatment and Policy" Conference, on February 3-4, 2017 for up to a total of 13 CEU's for Social Workers.